Benzinga · Nov 13, 2026
Morgan Stanley Maintains Overweight on argenx, Lowers Price Target to $1130
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1190 to $1130.
NASDAQ · ARGX
Healthcare · Biotechnology
$941.25
Up+$0.79 (+0.08%)
Updated Nov 20, 2026, 1:56 AM
SID Score
5.9/10
Composite research score
Smart Money
56/100
Neutral
Price performance · ARGX
1M range · 0 trading sessions · Daily adjusted prices
ARGX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ARGX.
Company
Market Activity
Research & News
ARGX research
Company profile and research snapshot.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 22, 2026 | BNP PARIBAS | Outperform | — |
| Sep 22, 2026 | TD COWEN | Buy | — |
| Sep 21, 2026 | DAY BY DAY | Buy | — |
| Sep 14, 2026 | KBC SECURITIES | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 13, 2026
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1190 to $1130.
Yahoo · Nov 10, 2026
argenx has delivered strong share price gains in recent years, so the immediate question for investors is whether today’s valuation can be explained by the company’s earnings power. With sentiment also shaped by fresh clinical and deal news, the current price invites a closer look at what the profit profile really supports. Over the past 5 years argenx has returned 227.0%. That puts real weight on whether the profit stream behind the stock can carry that kind of move. The planned acquisition...
SeekingAlpha · Nov 10, 2026
argenx is a Hold with its $550M Unnatural Products deal for an unproven pipeline that may pressure commercial products and R&D. Read more on ARGX stock here.
Yahoo · Nov 9, 2026
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ARGX.